Oral Presentations
The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.
Saturday, 15 June 2024
Abstract S207
Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-year Follow-up in All Patients
Presenting author: Binod Dhakal
Session: CAR T cell therapy for the treatment of Multiple Myeloma
Hall Picasso •
17:00 – 17:15
Abstract S334
The Cost-Effectiveness of Axicabtagene Ciloleucel versus Standard of Care as Second-Line Therapy in Patients with Large B-Cell Lymphoma in Sweden
Presenting author: Viktor Hedlof Kanje
Session: Quality of life and palliative care
Hall N104 •
17:30 - 17:45
Poster Presentations
The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.
Friday, 14 June 2024
Abstract P1159
ZUMA-24 Preliminary Analysis: A Phase 2 Study of Axicabtagene Ciloleucel in the Outpatient Setting with Prophylactic Corticosteroids in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Presenting author: Lori Leslie
Session: Aggressive Non-Hodgkin Lymphoma – Clinical
Hall 7 • 18:00 - 19:00
Abstract P1191
Updated Trends in Real-World Outpatient (OP) Administration of Axicabtagene Ciloleucel (Axi-Cel) and Brexucabtagene Autoleucel (Brexu-Cel) in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
Presenting author: Radhika Bansal
Session: Aggressive Non-Hodgkin Lymphoma – Clinical
Hall 7 • 18:00 - 19:00
Abstract P1199
Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada
Presenting author: Christopher Lemieux
Session: Aggressive Non-Hodgkin Lymphoma – Clinical
Hall 7 • 18:00 - 19:00
Abstract P1217
Cost-effectiveness and Budget Impact Analyses of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in Singapore
Presenting author: Francesca Lim
Session: Aggressive Non-Hodgkin Lymphoma – Clinical
Hall 7 • 18:00 - 19:00
Abstract P2092
Complete Response at 6 Months is Associated with Overall Survival After 1L Chemoimmunotherapy for High-Risk Diffuse Large B-Cell Lymphoma: A Pooled Clinical Trial Analysis
Presenting author: Ran Reshef
Session: Aggressive Non-Hodgkin Lymphoma – Clinical
Hall 7 • 18:00 - 19:00
Abstract P2088
Real-World Safety Outcomes of Axicabtagene Ciloleucel in Patients with Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Europe and United States: A Systematic Review and Meta-Analysis
Presenting author: Robin Sanderson
Session: Aggressive Non-Hodgkin Lymphoma – Clinical
Hall 7 • 18:00 - 19:00
Abstract P1425
Real-World Manufacturing Experience of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated in Second Line versus Third Line of Therapy and Beyond
Presenting author: Jason Westin
Session: Gene therapy, cellular immunotherapy and vaccination - Biology & translational research
Hall 7 • 18:00 - 19:00
Abstract P1666
Treatment Preferences and Quality of Life in Patients with Relapsed/Refractory Follicular Lymphoma
Presenting author: John Gribben
Session: Quality of life and palliative care
Hall 7 • 18:00 - 19:00
Publications
The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.
PB2724 (ePublication)
iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) with Standard of Care in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Tom Martin
iMMagine-3 Trial in Progress
PB3430 (Publication-only)
Sustained Cost-Effectiveness of Brexucabtagene Autoleucel for the Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 26 Years or Older in Italy
Monica Marchetti
Acute Lymphoblastic Leukemia
*Presentation time and date subject to change.
